01
Abalos is harnessing its unique AdaptInnate approach to develop a new class of systemically administrable candidates that trigger precise innate and adaptive immune responses from within a patient’s tumor

Treating Cancer
from Within

01
Abalos was founded to translate an innovative arenavirus-based immune-activating approach into novel anti-cancer therapies

Scientific
Foundation

01
Stay up to date on news around Abalos

News &
Events

ABOUT ABALOS THERAPEUTICS

Triggering comprehensive immune responses from within the tumor

novel anti-cancer approach

Abalos’ transformative treatment strategy enables multiple actors of the immune system to uncloak cancerous cells and break down tumors. Our platform technologies generate drug candidates that achieve persistent and far-reaching inflammation within the tumor. Delivered systemically, the approach safely engages all key immune organs in a concerted attack against tumors and distant metastases. Building on strong preclinical safety and targeted anti-tumor activity, Abalos’ lead candidate ABX-001 will enter the clinic in 2025. Our mission is to develop a pipeline of both naturally optimized as well as payload-carrying therapeutics designed for specific cancer indications, bringing better treatments to more patients.

ABOUT ABALOS THERAPEUTICS

Abalos Dunes on Mars

why abalos?

The name “Abalos” was chosen with regards to our arenavirus-based technology to fight cancer. The name of this virus family derives from the Latin “arena” for “sand” due to the grainy appearance of particles inside the virus when viewed in cross-section under the transmission electron microscope. Reflecting our “sandy” approach, we came upon the fascinating blue dunes of the Abalos region on the otherwise “red” Mars, a planet that has always held a special fascination.

Named after the roman war god and its association with fire, it provides a connection to harnessing the weapon of the arenavirus to launch an attack against cancer. As Mars is also known as a planet of sand storms, this can be associated with the strong immune-response that is triggered by the arenavirus to attack the tumor.

ABALOS TECHNOLOGY

Therapeutic Approach

Abalos is leveraging its proprietary AdaptInnate approach to develop a new class of product candidates harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to trigger a highly precise and directed immune response against primary tumors and their metastases. Abalos’ systemically administrable lead candidate, ABX-001, is specifically designed to persist and replicate in cancerous and antigen-presenting cells without destroying them. This novel, non-oncolytic approach results in the induction of targeted, effective, and durable anti-tumor activity involving both the innate and adaptive arms of the immune system.

This is Abalos

Meet the Team

A dynamic and ambitious group of experienced entrepreneurs and scientists advancing a novel immunostimulatory approach that (re)activates the full breadth of the immune system against solid tumors.

Abalos Team

Read more about the Team here.

Latest News & Events

Stay up to date on news around Abalos.

Our Support

Investors & Partners

ABALOS THERAPEUTICS IS SUPPORTED BY A SYNDICATE OF PRESTIGIOUS LIFE SCIENCE INVESTORS AND PARTNERS